| __timestamp | Apellis Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 1860000 |
| Thursday, January 1, 2015 | 6356782 | 2963000 |
| Friday, January 1, 2016 | 4303743 | 6961000 |
| Sunday, January 1, 2017 | 10463151 | 11779000 |
| Monday, January 1, 2018 | 22639184 | 13697000 |
| Tuesday, January 1, 2019 | 67046483 | 15749000 |
| Wednesday, January 1, 2020 | 139401000 | 18638000 |
| Friday, January 1, 2021 | 176771000 | 27196000 |
| Saturday, January 1, 2022 | 277163000 | 31739000 |
| Sunday, January 1, 2023 | 500815000 | 33491000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. over the past decade.
From 2014 to 2023, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing from approximately $2.9 million to over $500 million. This represents a growth of over 17,000%, reflecting the company's aggressive expansion and investment in its operations. In contrast, Protagonist Therapeutics has maintained a more conservative growth trajectory, with expenses rising from $1.9 million to $33.5 million, a growth of about 1,660%.
The stark difference in SG&A growth rates highlights varying strategic approaches. Apellis's rapid increase suggests a focus on scaling and market penetration, while Protagonist's steadier rise may indicate a more cautious, sustainable growth strategy.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Viatris Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights